Common

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Retrieved on: 
Monday, March 4, 2024

HOUSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Key Points: 
  • The presentations shed light on cutting-edge developments in genetic analysis, diagnostic interpretation, and clinical results, underscoring Baylor Genetics’ mission to translate scientific innovation into accessible clinical solutions that improve patient outcomes and advance precision diagnostics.
  • "These presentations reflect our ongoing commitment to advancing the field of genetics and empowering patients, providers, and partners with insights and innovations to transform healthcare and improve lives."
  • Customers and partners interested in attending the breakfast can request an invitation and register here or inquire onsite at the Baylor Genetics booth.
  • Learn more about ACMG’s Annual Clinical Genetics Meeting through the conference website and visit the Baylor Genetics’ website to explore the company’s genetic testing capabilities.

Latitude Uranium Announces Voting Results from Special Meeting

Retrieved on: 
Tuesday, February 27, 2024

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce that shareholders of the Company (the “Shareholders”) have overwhelmingly approved the previously announced arrangement (the “Arrangement”) involving the Company and ATHA Energy Corp. (“ATHA”) at the Company’s special meeting (the “Meeting”) held today.

Key Points: 
  • TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce that shareholders of the Company (the “Shareholders”) have overwhelmingly approved the previously announced arrangement (the “Arrangement”) involving the Company and ATHA Energy Corp. (“ATHA”) at the Company’s special meeting (the “Meeting”) held today.
  • The special resolution approving the Arrangement (the “Arrangement Resolution”) was required to be approved by at least two-thirds (66 2/3%) of the votes cast by Shareholders present virtually or represented by proxy at the Meeting.
  • A total of 103,295,471 common shares of LUR ("Common Shares”), representing approximately 44.69% of votes entitled to be cast at the Meeting, were represented proxy at the Meeting.
  • Subject to the satisfaction of these closing conditions, the parties currently expect to complete the Arrangement in early March 2024.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Tuesday, February 27, 2024

Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.

Key Points: 
  • Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.
  • Presented additional patient-reported outcome data from the Phase 3 DeFi trial at the 2023 Connective Tissue Oncology Society Annual Meeting.
  • Revenues: OGSIVEO net product revenues were $5.4 million in the fourth quarter of 2023, the first partial quarter of the U.S. launch.
  • Cash Position: Cash, cash equivalents and marketable securities were $662.6 million as of December 31, 2023.

Entro Extends Machine Secrets and Identities Protection With Machine Identity Lifecycle Management, More Integrations

Retrieved on: 
Tuesday, February 27, 2024

It also helps enforce best practices for managing secrets in CI/CD pipelines, communication and collaboration platforms, and for retiring secrets and other critical lifecycle events.

Key Points: 
  • It also helps enforce best practices for managing secrets in CI/CD pipelines, communication and collaboration platforms, and for retiring secrets and other critical lifecycle events.
  • The company also announced new integrations of the Entro platform with CIFS/SMB File Shares and Microsoft SharePoint.
  • Already a pioneer transforming non-human identity management, Entro is the first holistic secrets security platform that detects, safeguards and enriches with context, machine and non-human identities.
  • The new Machine Identity Lifecycle Management and integration capabilities build on Entro’s proven technology to rapidly discover all the context surrounding machine secrets from vaults to app code to the dark web.

HydroGraph Announces Closing of Second Tranche of Private Placement

Retrieved on: 
Monday, February 26, 2024

VANCOUVER, British Columbia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGCPF) (the “Company” or “HydroGraph”) announces that the Company has closed the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”) previously announced on October 30, 2023. Pursuant to the Second Tranche, the Company issued an aggregate of 9,626,000 units of the Company (the “Units”) for aggregate gross proceeds of C$962,600. The Units were offered in US dollars and Canadian dollars at the respective prices of US$0.074 and C$0.10. To date, HydroGraph has sold and issued an aggregate of 19,886,856 Units for gross proceeds of approximately C$1.99 million pursuant to the Offering.

Key Points: 
  • Not for distribution to U.S. newswire services or dissemination in the United States
    VANCOUVER, British Columbia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGCPF) (the “Company” or “HydroGraph”) announces that the Company has closed the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”) previously announced on October 30, 2023.
  • Pursuant to the Second Tranche, the Company issued an aggregate of 9,626,000 units of the Company (the “Units”) for aggregate gross proceeds of C$962,600.
  • To date, HydroGraph has sold and issued an aggregate of 19,886,856 Units for gross proceeds of approximately C$1.99 million pursuant to the Offering.
  • One insider of the Company participated in the Second Tranche and subscribed for a total of 250,000 Units for gross proceeds of C$25,000.

Unblock Health and Health Gorilla Announce Collaboration to Enhance Patient Data Access through TEFCA

Retrieved on: 
Monday, February 26, 2024

Unblock Health will participate in Health Gorilla’s QHIN to enable patients to retrieve their personal health records under the Individual Access Services (IAS) purpose of use.

Key Points: 
  • Unblock Health will participate in Health Gorilla’s QHIN to enable patients to retrieve their personal health records under the Individual Access Services (IAS) purpose of use.
  • As a QHIN, Health Gorilla supports data exchange for multiple purposes of use, including Treatment, Payment, Health Care Operations, Public Health, Government Benefits Determination, and IAS.
  • Unblock Health is collaborating with Health Gorilla on IAS solutions to ensure that patients can seamlessly and securely access their data from a vast network of participating hospitals and clinics.
  • “We are proud to collaborate with Grace and the Unblock Health team, who have proven a relentless commitment to empowering patients through access to their health data.

Celularity Announces 1-for-10 Reverse Stock Split

Retrieved on: 
Friday, February 23, 2024

Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.

Key Points: 
  • Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.
  • Correspondingly, the exercise price per share of Class A common stock attributable to such warrants immediately prior to the reverse stock split has been proportionately increased, such that the exercise price immediately following the reverse stock split is $115.
  • Continental Stock Transfer and Trust, Celularity’s transfer agent, will act as the exchange agent for the reverse stock split.
  • In connection with the reverse stock split, the CUSIP number for Celularity’s post-split Class A common stock will change to 151190 204.

Treasure Global Announces 1:70 Reverse Stock Split

Retrieved on: 
Friday, February 23, 2024

NEW YORK and KUALA LUMPUR, Malaysia, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, announced today that it will effect a 1-for-70 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.00001 per share (“Common Stock”).

Key Points: 
  • NEW YORK and KUALA LUMPUR, Malaysia, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, announced today that it will effect a 1-for-70 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.00001 per share (“Common Stock”).
  • The 1-for-70 reverse stock split will automatically combine and convert seventy current shares of the Common Stock into one issued and outstanding new share of Common Stock.
  • The Reverse Stock Split will not change the par value of the Common Stock nor the authorized number of shares of Common Stock, preferred stock or any series of preferred stock.
  • Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split and will not be required to take any action in connection with the Reverse Stock Split.

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

Retrieved on: 
Friday, February 23, 2024

TARRYTOWN, N.Y. and PARIS, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The target action date for the FDA decision is June 27, 2024. Regulatory submissions are under review in China and Europe.

Key Points: 
  • The target action date for the FDA decision is June 27, 2024.
  • Regulatory submissions are under review in China and Europe.
  • In both trials, Dupixent rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
  • Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Retrieved on: 
Friday, February 23, 2024

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).
  • The target action date for the FDA decision is June 27, 2024.
  • In both trials, Dupixent also rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
  • Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.